Understanding celiac disease monitoring patterns and outcomes after diagnosis: A multinational, retrospective chart review study

Table 3 Descriptive characteristics of follow-up visits and endoscopies during the follow-up period, overall and by country

		Overall	United Kingdom	United States	Norway
Length of follow-up time1 (mo)	Mean (SD)	29.9 (22.1)	26.5 (20.9)	38.7 (22.8)	24.5 (20.1)
	Median (IQR)	25 (12-47)	21 (9-42)	39.5 (17-60)	16 (12-32.5)
Number of follow-up visits (per patient)	Mean (SD)	3.0 (2.3)	2.7 (2.5)	4.0 (2.4)	2.3 (1.5)
	Median (IQR)	2 (1-4)	2 (1-3)	4 (2-6)	2 (1-3)
Number of follow-up visits with biopsy data (per patient)	Mean (SD)	0.7 (0.8)	0.5 (0.7)	0.3 (0.5)	1.2 (0.9)
	Median (IQR)	0.5 (0-1)	0 (0-1)	0 (0-1)	1 (1-1.5)
Endoscopy with duodenal biopsy during follow-up
Yes	n (%)	150 (50.0)	42 (42.0)	26 (26.0)	82 (82.0)
No	n (%)	150 (50.0)	58 (58.0)	74 (74.0)	18 (18.0)
If ‘Yes’, number of endoscopies with duodenal biopsy during follow-up
1	n (%)	116 (77.3)	37 (88.1)	22 (84.6)	57 (69.5)
2	n (%)	22 (14.7)	3 (7.1)	4 (15.4)	15 (18.3)
3	n (%)	9 (6.0)	1 (2.4)	0 (0.0)	8 (9.8)
> 3	n (%)	3 (2.0)	1 (2.4)	0 (0.0)	2 (2.4)
Timing of endoscopy with duodenal biopsy during follow-up2
< 12 mo	n (%)	45 (30.0)	18 (42.9)	3 (11.5)	24 (29.3)
12-24 mo	n (%)	63 (42.0)	11 (26.2)	6 (23.1)	46 (56.1)
> 24 mo	n (%)	64 (42.7)	19 (45.2)	18 (69.2)	27 (32.9)

For unknown diagnosis days and months, the day was imputed to the 15^th, and the month was imputed to June.

¹Length of time from diagnosis to last follow-up available in charts, within the study period.

²Total percentage may be greater than 100%.

IQR: Interquartile range; SD: Standard deviation.